BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Empagliflozin/prednisoneReactions Weekly 2019; 1748(1): 196 doi: 10.1007/s40278-019-60112-0
2
Mortaza F. Hassanabad, Zahra F.H. Abad. Are SGLT2 inhibitors joining the mainstream therapy for diabetes type 2?Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019; 13(3): 1893 doi: 10.1016/j.dsx.2019.04.041